NDA 208224 · Bayer Hlthcare
Kyleena
Levonorgestrel · Intrauterine · Progestin; Progestin-containing Intrauterine System
Last checked: Nov 20, 2026Latest source record: May 4, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Sep 16, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
354
70 Phase 3, 26 recruiting
FAERS reports
11,993
5,950 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 23, 2025.
Kyleena is indicated to prevent pregnancy for up to 5 years. Replace the system after 5 years if continued use is desired. Kyleena is a progestin-containing intrauterine system (IUS) indicated for prevention of pregnancy for up to 5 years. ( 1 )
Mechanism: The local mechanism by which continuously released LNG contributes to the contraceptive effectiveness of Kyleena has not been conclusively demonstrated. Studies of Kyleena and similar LNG IUS prototypes have suggested several mechanisms that prevent pregnancy: thickening of cervical mucus preventing passage of sperm into the uterus, inhibition of sperm capacitation or survival, and alteration of the endometrium .
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- KYLEENA · LEVONORGESTREL 19.5MG · SYSTEM, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00528112 · 2,885 participants · Start Aug 2007 · Primary completion Jul 2011
Drug: LCS12; LCS16 · For: Contraception
Sites: Mobile, Alabama; Glendale, Arizona; Phoenix, Arizona · 136 sites in all
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00551616 · 2,221 participants · Start Apr 2007 · Primary completion Apr 2009
Drug: CDB-2914; Levonorgestrel · For: Contraception
Sites: Los Angeles, California; Santa Monica, California; Boulder, Colorado · 33 sites in all
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)Pivotal-lookingTerminated
Organon and CoIndustry
NCT02616146 · 2,016 participants · Start Dec 1, 2015 · Primary completion Oct 6, 2016
Drug: ENG-E2 125 μg/300 μg vaginal ring; LNG-EE 150 μg/30 μg COC · For: Contraception
Sites: Vienna, Austria; San José, Costa Rica; Glostrup Municipality, Denmark · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device expulsion2,145
- device dislocation1,616
- drug ineffective1,128
- genital haemorrhage824
- complication of device insertion674
- abdominal pain lower662
- pregnancy with contraceptive device487
- procedural pain426
- ectopic pregnancy with contraceptive device384
- nausea337
- vaginal haemorrhage330
- headache295
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 39 |
| 2006 | 37 |
| 2007 | 27 |
| 2008 | 22 |
| 2009 | 45 |
| 2010 | 64 |
| 2011 | 93 |
| 2012 | 101 |
| 2013 | 45 |
| 2014 | 33 |
| 2015 | 72 |
| 2016 | 119 |
| 2017 | 395 |
| 2018 | 934 |
| 2019 | 1,206 |
| 2020 | 1,548 |
| 2021 | 1,375 |
| 2022 | 1,391 |
| 2023 | 1,411 |
| 2024 | 1,168 |
| 2025 | 1,041 |
| 2026 | 788 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kyleena (Levonorgestrel)
2024 spending
$43K
Beneficiaries
38
38 claims
Per beneficiary
$1,134
$1,134.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,660 |
| 2021 | $37,600 |
| 2022 | $40,248 |
| 2023 | $48,910 |
| 2024 | $43,096 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- The norgestrel-T-IUD.
El-Mahgoub S · Contraception 1980 · Clinical Trial, Randomized Controlled Trial
- Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis.
Suzuki Y, Ferris JS, Chen L, et al. · Am J Obstet Gynecol 2024 · Systematic Review, Meta-Analysis
- Do COX-inhibitors improve emergency contraception efficacy?
· Drug Ther Bull 2024 · Randomized Controlled Trial
- Progestin-only pills for contraception.
Grimes DA, Lopez LM, O'Brien PA, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, N.I.H., Extramural
- Metformin for endometrial hyperplasia.
Shiwani H, Clement NS, Daniels JP, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.